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inhibition by semagacestat in Alzheimer’s disease
Rachelle S Doody1, Rema Raman2,3, Reisa A Sperling4, Eric Seimers5, Gopalan Sethuraman5, Richard Mohs5,
Martin Farlow6, Takeshi Iwatsubo7, Bruno Vellas8, Xiaoying Sun9, Karin Ernstrom9, Ronald G Thomas3,10,
and Paul S Aisen3* for the Alzheimer’s Disease Cooperative StudyAbstract
Introduction: The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate
Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed
these data to explore relationships between drug exposure and pharmacodynamic effects and to examine the
correlations among outcome measures.
Methods: The study was a multicenter, randomized, placebo-controlled trial of two dose regimens of semagacestat
and a placebo administered for 18 months to individuals with mild to moderate AD. Changes in measures of central
and peripheral drug activity were compared between the three treatment groups using one-way analysis of variance.
The relationship between changes in each of the outcome measures and measures of drug exposure and peripheral
pharmacodynamic effect were assessed using Spearman’s correlation coefficient.
Results: Assignment to the active treatment arms was associated with reduction in plasma amyloid-β (Aβ) peptides,
increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (p-tau) and several other laboratory
measures and adverse event categories. Within the active arms, exposure to drug, as indicated by area under the
concentration curve (AUC) of blood concentration, was associated with reduction in plasma Aβ peptides and a
subset of laboratory changes and adverse event rates. Ventricular volume increase, right hippocampal volume
loss and gastrointestinal symptoms were related to change in plasma Aβ peptide but not AUC, supporting a link
to inhibition of γ-secretase cleavage of the amyloid precursor protein. Cognitive decline correlated with ventricular
expansion and reduction in p-tau.
Conclusion: These findings may inform future studies of drugs targeting secretases involved in Aβ generation.
Trial registration: ClinicalTrials.gov Identifier: NCT00594568. Registered 11 January 2008.Introduction
One leading theory of the pathogenesis of Alzheimer’s
disease (AD) considers the sequential cleavage of the
amyloid precursor protein (APP) by β- and γ-secretases
to release amyloidogenic peptides to be the initiating
and driving event in this neurodegenerative condition
[1]. Inhibition of secretases has therefore been a major
strategy in efforts to develop disease-modifying treat-
ments for AD [2]. The strategy of γ-secretase inhibition
to slow disease progression is further supported by the
finding that the most common mutations that cause* Correspondence: paisen@ucsd.edu
3Department of Neurosciences, University of California San Diego, 9500
Gilman Drive, M/C 0949, La Jolla, CA 92093, USA
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unless otherwise stated.familial autosomal dominant AD involve presenilin, a
γ-secretase component [3].
The first large-scale study of a γ-secretase modulating
drug, flurbiprofen, was ineffective [4]. This failure has
been attributed to insufficient pharmacodynamic effects
in the brain. More recently, novel γ-secretase inhibitors
have demonstrated target engagement, as indicated by
reduction in cerebrospinal fluid (CSF) levels of amyloid
peptides [5,6]. A major concern about this drug class
has been adverse effects related to impact on non-target
substrates [6-8]. In particular, Notch cleavage by γ-secretase
may be inhibited by such drugs [9], with adverse effects on
the gastrointestinal, immune and cutaneous systems.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inhibitor, but we note that it increases levels of amyloid-
β peptide 42 (Aβ42) in the blood at low concentrations,
suggesting that it may exert its activity at an allosteric
site rather than the active site of the enzyme. It does
not increase generation of shorter peptides (such as
Aβ38), which is a characteristic of drugs referred to as
γ-secretase modulators.
Semagacestat was the first γ-secretase inhibitor to
reach Phase III testing in AD. The development of this
drug was spurred by strong evidence for a central phar-
macodynamic effect in a study in which researchers used
stable isotope labeling with CSF sampling to determine
the kinetics of amyloid peptide production [7]. The phase
III trial, the primary results of which are reported else-
where [10], was terminated before planned completion
because of evidence of cognitive and other adverse ef-
fects in the active treatment group. Data derived from
the trial afford an opportunity to evaluate the periph-
eral laboratory and clinical effects and the central effects of
γ-secretase inhibition in AD. This experience may inform
other ongoing efforts to target this enzyme complex.
Methods
Patients, drug dosing and blinding
The present study was approved by the institutional review
boards at each participating site (see Additional file 1).
Subjects aged 55 years or older with mild to moderate AD
(Mini Mental State Examination (MMSE) [11] score
between 16 and 26 at screening) who met National Institute
of Neurological and Communicative Disorders and Stroke/
Alzheimer’s Disease and Related Disorders Association
criteria [12] and were in good general health and free
of depression (Geriatric Depression Scale score ≤6)
[13]) were randomized to escalate to 100 mg once daily
or 140 mg once daily of semagacestat or placebo over
76 weeks using a triple dummy to blind dosage groups.
Doses were titrated as follows: 60 mg for 2 weeks, then
100 mg; or 60 mg for 2 weeks, 100 mg for 2 weeks,
then 140 mg. At baseline, subjects could be untreated
or treated with background cholinesterase inhibitors
with or without memantine, as long as they had been
on the drug for at least 4 weeks and the doses of anti-
dementia drugs were stable for at least 2 months. All
subjects signed informed consent forms prior to par-
ticipating in study procedures.
Cognitive measures
Patients were assessed with the 11-item version of the
Alzheimer’s Disease Assessment Scale–Cognitive Subscale
(ADAScog11) [14] at baseline and weeks 12, 28, 40, 52,
64, 76 and 88 or at early termination and with the MMSE
at screening, baseline and weeks 52, 76 and 88 or early
termination.Biological markers and imaging outcome measures
Patients were genotyped for apolipoprotein E polymor-
phisms. Special lymphocyte hematology was done at
baseline and weeks 12, 28, 40, 52, 64, 76 and 88 or early
termination. Plasma Aβ was assessed at baseline and
weeks 6, 12 and 52 or early termination. Optional CSF
analysis for Aβ peptides and tau and phosphorylated
tau (p-tau) proteins was conducted in willing subjects.
Volumetric magnetic resonance imaging (vMRI), amyl-
oid imaging with florbetapir (AV45) fludeoxyglucose
positron emission tomography (FDG-PET), and CSF
analyses were performed at baseline and week 76 or early
termination. Additional details regarding methods are
provided in the Appendix to the article describing the pri-
mary results of the phase III trial [10].
Pharmacokinetic measures
Pharmacokinetic (PK) samples were collected at week 6,
12 and 52. Population PK analysis was performed using
a nonlinear mixed-effects model. The model estimated
individual clearance values for each subject using all
concentrations collected at each visit, taking into ac-
count time from dose, the dose level administered, and
estimated residual error that resulted from assay error,
inaccurate sample time information or inaccurate dosing
information. The clearance estimate for each individual
was used to calculate area under the concentration curve
(AUC) using standard equations. A similar process was
undertaken to generate maximum concentration (Cmax)
using standard equations to calculate Cmax and individ-
ual estimates for various PK parameters.
Alzheimer’s Disease Cooperative Study Data Analysis and
Publication Committee
The Data Analysis and Publication Committee (DAPC)
was funded by a grant from Eli Lilly to the University of
California at San Diego as fiduciary for the Alzheimer’s
Disease Cooperative Study (ADCS) after the semagace-
stat phase III studies were halted, but before the datasets
were transferred to the ADCS. The timing of the con-
tract was designed to remove any concern that payment
for the work of data analysis and publication would be
dependent upon the outcome. The DAPC developed a
document of governance that specifies voting members
of the committee, as well as non-voting members, who
include a limited number of Eli Lilly employees who are
familiar with the study and the data and one non-voting
representative each of the Data Safety Monitoring
Committee and the National Institute on Aging. The
DAPC also developed a data dissemination plan and
kept the ADCS Steering Committee apprised of its
progress by formal reports at each Steering Committee
meeting. The final publication was developed by the
committee and approved by the voting members of the
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and non-voting DAPC members gave feedback but did
not have veto power.
Statistical analysis
Changes in outcome measures reflecting central and
peripheral activity of semagacestat were compared be-
tween the three treatment groups using one-way analysis
of variance. Analyses included all randomized subjects
with available data. Annualized change from baseline in
cognitive, CSF and three imaging outcomes (vMRI,
FDG-PET and AV45) were calculated based on the last
available observation in the initial treatment period. The
outcome for plasma Aβ used percentage change from
baseline to 6 hours postdose at week 52. Laboratory
measures included change from baseline in uric acid, albu-
min and eosinophils at week 76. Specific adverse events,
including gastrointestinal, skin disorder, skin cancer and
infection incidence, were compared between the three
treatment groups using the Fisher-Freeman-Halton exact
test. The relationship between change in each of the out-
come measures (cognitive tests, plasma Aβ, CSF assays,
vMRI, FDG-PET and rates of specific adverse events) andTable 1 Outcomes by treatment armsa
Placebo
Annualized change in ADASCog11 4.75 ± 21.92 (n = 485)
Annualized change in MMSE −2.19 ± 3.65 (n = 396)
Annualized change in FDG-PET SUVR −0.06 ± 0.07 (n = 40)
Annualized change in AV45 SUVR 0.05 ± 0.11 (n = 18)
Annualized change in ventricular volume 4.07 ± 3.52 (n = 80)
Annualized change in right hippocampal volume −86.28 ± 73.86 (n = 74
Annualized change in left hippocampal volume −68.85 ± 59.01 (n = 74
Annualized change in CSF Aβ40 87.66 ± 847 (n = 10)
Annualized change in CSF Aβ42 10.96 ± 87.66 (n = 10)
Annualized change in p-tau 10.96 ± 7.31 (n = 10)
Annualized change in total tau 94.97 ± 116.9 (n = 10)
Percentage change in plasma Aβ40 at week 52 4.77 ± 26.67 (n = 307)
Percentage change in plasma Aβ42 at week 52 3.82 ± 20.75 (n = 309)
Change in uric acid at week 76 0.18 ± 0.83 (n = 210)
Change in albumin at week 76 0 ± 0.25 (n = 210)
Change in eosinophils at week 76 −0.001 ± 0.09 (n = 207
Gastrointestinal symptoms 153 (31.5%)
Skin disorder incidence 105 (21.6%)
Skin cancer incidence 8 (1.7%)
Infection incidence 156 (32.1%)
AUC
Cmax
aAβ40, Amyloid-β peptide 40; Aβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s
under the curve; AV45, Florbetapir; Cmax, Maximum concentration; CSF, Cerebrospin
Semagacestat; MMSE, Mini Mental State Examination; p-tau, Phosphorylated taumeasures of drug exposure (AUC in the active treatment
group) and peripheral pharmacodynamic effects (changes
in plasma Aβ) were assessed using Spearman’s correlation
coefficient [15]. R version 2.14.1 statistical software [16]
was used for all statistical analyses. We did not employ
corrections for multiple comparisons in this exploratory
analysis.
Results
Outcomes by treatment group
Summary statistics of key outcomes are shown in Table 1
for the three arms of the trial. Treatment assignment
was associated with ventricular volume (greater ventricu-
lar expansion in high-dose arm), CSF p-tau (increase in
placebo arm, reduction in treatment arms), plasma Aβ
peptides (dose-related reduction in active arms) and sev-
eral laboratory measures and adverse event categories
(Table 1). The relationship between arm assignment and
change in plasma Aβ peptides is shown in Figure 1. Levels
of both species of amyloid peptide had declined in both
active treatment arms by week 6, and the reductions were
sustained until week 52 (the final analysis time point for
plasma amyloid peptides).LY 100 mg LY 140 mg P-value
6.57 ± 25.57 (n = 482) 5.48 ± 21.92 (n = 495) 0.408
−2.56 ± 3.65 (n = 324) −2.92 ± 3.65 (n = 303) 0.159
−0.13 ± 0.21 (n = 42) −0.1 ± 0.08 (n = 33) 0.109
0.02 ± 0.24 (n = 23) 0.07 ± 0.23 (n = 18) 0.794
4.19 ± 3.92 (n = 74) 5.68 ± 4.68 (n = 67) 0.033
) −91.08 ± 102.1 (n = 68) −90.98 ± 71.1 (n = 64) 0.926
) −70.4 ± 90.81 (n = 68) −91.0 ± 101.2 (n = 64) 0.244
−10.96 ± 1151 (n = 19) −599 ± 1786 (n = 18) 0.328
−40.18 ± 109.6 (n = 19) −36.5 ± 182.7 (n = 18) 0.619
−7.31 ± 14.61 (n = 19) −3.65 ± 10.96 (n = 18) 0.009
−43.83 ± 219.2 (n = 17) 40.18 ± 127.8 (n = 18) 0.101
−37.54 ± 109.3 (n = 264) −47.76 ± 32.06 (n = 243) <0.001
−5.4 ± 53.1 (n = 265) −18.14 ± 33.0 (n = 245) <0.001
−0.96 ± 1.08 (n = 179) −0.88 ± 1.22 (n = 147) <0.001
−0.09 ± 0.31 (n = 179) −0.09 ± 0.3 (n = 147) 0.002
) 0.05 ± 0.17 (n = 179) 0.06 ± 0.14 (n = 143) <0.001
169 (34.9%) 193 (38.8%) 0.057
220 (45.4%) 269 (54%) <0.001
51 (10.5%) 56 (11.2%) <0.001
188 (38.8%) 220 (44.2%) <0.001
5,316 ± 1,525 (n = 480) 7,235 ± 2233 (n = 494) <0.001
1,105 ± 260 (n = 480) 1,508 ± 384 (n = 494) <0.001
Disease Assessment Scale–Cognitive Subscale, 11-item version; AUC, Area
al fluid; FDG-PET, Fludeoxyglucose positron emission tomography; LY,
; SUVR, Standard uptake value ratio.
Figure 1 Change in plasma amyloid-β peptide levels. Abeta, Amyloid-β; LY100mg, Semagacestat 100 mg; LY140mg, Semagacestat 140 mg.
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increasing dose, although there was overlap between the
dose groups.
Correlational analyses
Among adverse events, correlational analyses suggested
that gastrointestinal symptoms, rash and skin cancer
may be related to each other, while uric acid reduction,
albumin reduction and infection formed a cluster (Table 2).
Among markers of central nervous system effects, decline
in cognition measured either by increase in ADAScog11
score or decrease in MMSE score correlated with each
other and with ventricular expansion (Table 3). Consistent
with the overall groupwise effects, there was an unex-
pected correlation between reduction in CSF p-tau and
cognitive decline.
To determine whether clinical and laboratory effects were
more closely associated with drug exposure or with theTable 2 Correlations between peripheral biomarkersa
AUC Plasma Aβ40 Uric acid Albumin E
AUC 1; 0 −0.36; 0.001 −0.15; 0.007 −0.14; 0.01 0
Plasma Aβ40 1; 0 −0.01; 0.86 0.131; 0.03 −
Uric acid 1; 0 0.08; 0.13 −
Albumin 1; 0 −
EOS 1
GI
Skin
Skin cancer
Infection
aAβ40, Amyloid-β peptide 40; AUC, Area under the concentration curve; EOS, Eosin
P-values (r; P).target pharmacodynamic effects (inhibition of γ-secretase
cleavage of the APP to release amyloidogenic peptides), we
examined the correlation between measures and semagace-
stat AUC and change in plasma Aβ40, respectively (Table 4).
We used Aβ40 rather than Aβ42 because the latter values
were confounded in some cases by measurement below the
level of detection.
Uric acid reduction was correlated to drug exposure
but not to plasma Aβ change, suggesting a mechanism
distinct from inhibition of APP cleavage such as drug-
induced Fanconi syndrome. Reduction in serum albumin
and increase in eosinophil counts correlated with both
AUC and reduction in plasma Aβ. There was a trend re-
lating decrease in FDG PET SUVR to AUC, but no re-
lationship with change in plasma Aβ reducing the
likelihood that the proposed pharmacological mechan-
ism of the drug influenced FDG signal. In contrast,
gastrointestinal symptoms were related to plasma AβOS GI Skin Skin cancer Infection
.18; 0.001 0.02; 0.65 −0.02; 0.63 −0.01; 0.81 0.14; 0.001
0.19; 0.002 −0.10; 0.03 −0.08; 0.06 −0.08; 0.09 −0.07; 0.11
0.23; 0.001 0.03; 0.60 −0.12; 0.04 −0.08; 0.13 −0.11; 0.04
0.22; 0.001 0.05; 0.42 0.02; 0.72 0.02; 0.68 −0.15; 0.006
; 0 −0.01; 0.85 0.04; 0.50 0.11; 0.06 0.08; 0.17
1; 0 0.11; 0.001 0.05; 0.16 0.17; 0.001
1; 0 0.14; 0.001 0.13; 0.001
1; 0 0.123; 0.001
1; 0
ophils; GI, Gastrointestinal. Data are Spearman’s correlation coefficients and
Table 3 Correlations between changes in central biomarkersa
Ventricular volume CSF p-tau CSF Aβ42 ADAScog11 MMSE
FDG-PET SUVR −0.43; 0.007 −0.14; 0.79 0.37; 0.47 −0.11; 0.36 0.23; 08
Ventricular volume 1; 0 −0.14; 0.62 −0.12; 0.67 0.46; 0.001 −0.54; 0.001
CSF p-tau 1; 0 0.37; 0.49 −0.40; 0.02 0.33; 0.05
CSF Aβ42 1; 0 −0.12; 0.48 0.31; 0.08
ADAScog11 1; 0 −0.58; 0.001
aAβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 11-item version; CSF, Cerebrospinal fluid; FDG-PET,
Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio. Data
are Spearman’s correlation coefficients and P-values (r; P).
Doody et al. Alzheimer's Research & Therapy  (2015) 7:36 Page 5 of 7change but not to drug exposure, consistent with a
shared mechanism related to γ-secretase cleavage of
APP. Of note, MRI volumetric change, specifically at-
rophy as indicated by increase in ventricular volume,
was also correlated to change in plasma Aβ. Because
drug exposure and change in plasma Aβ40 are strongly
correlated, adjusting the correlations of each with the
other generally reduces the association of each meas-
ure; however, the relationship between change in
plasma Aβ40 and ventricular volume and right hippo-
campal volume were essentially unaffected by adjust-
ment for AUC.
Discussion
Semagacestat reduced plasma levels of Aβ peptides, con-
sistent with γ-secretase inhibition in the periphery. TheTable 4 Correlations of change in selected outcome measures
peptide 40 in the active armsa
Semagacestat AUC
r n P
Change in uric acid at week 76 −0.151 320 0.007
Change in albumin at week 76 −0.14 320 0.012
Gastrointestinal symptoms 0.015 943 0.654
Skin disorder incidence 0.016 943 0.627
Skin cancer incidence −0.012 943 0.71
Infection incidence 0.136 943 <0.001
Annualized change in FDG SUVR 0.22 74 0.06
Annualized change in ventricular volume 0.003 139 0.97
Annualized change in right hippocampal volume −0.064 130 0.472
Annualized change in left hippocampal volume −0.109 130 0.216
Annualized change in AV45 SUVR 0.133 40 0.414
Annualized change in ADASCog11 −0.012 938 0.707
Annualized change in MMSE 0.038 618 0.351
Annualized change in p-tau 0.02 37 0.909
Annualized change in total tau 0.07 35 0.691
Annualized change in CSF Aβ42 −0.13 37 0.443
aAβ40, Amyloid-β peptide 40; Aβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s
under the concentration curve; AV45, Florbetapir; CSF, Cerebrospinal fluid; FDG-PET
Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio.absence of an effect on CSF Aβ peptide levels was con-
sistent with the findings in the phase II trial [17] and
may have been related to the small numbers of lumbar
punctures and their timing in relation to dosing [7,17].
Thus, unlike our previous study in which we used the
stable isotope labeling kinetic technique [7], the available
data from this trial do not confirm adequate target en-
gagement in the central nervous system, clouding inter-
pretation of the results.
The most notable central nervous system effect was an
adverse effect on cognition in the high-dose arm, leading
to early termination of the trial, and a reduction in
change in CSF p-tau in the active arms compared with
placebo [10]. The p-tau effect is difficult to interpret. Al-
though it is consistent with a possible beneficial effect
on disease pathology, suggesting a link between Aβwith drug exposure and reduction in plasma amyloid-β
Change in plasma
Aβ40
AUC adjusted for
Aβ40
Aβ40 adjusted for
AUC
r n P r n P r n P
0.011 263 0.857 −0.149 260 0.016 0.071 260 0.255
−0.131 263 0.033 −0.037 260 0.548 −0.107 260 0.084
0.099 507 0.025 −0.004 501 0.933 0.094 501 0.034
0.083 507 0.062 −0.048 501 0.279 0.096 501 0.031
0.075 507 0.091 −0.039 501 0.389 0.084 501 0.059
0.072 507 0.101 0.068 501 0.129 0.042 501 0.344
<0.001 48 0.998 0.357 48 0.010 −0.134 48 0.364
0.242 91 0.021 −0.109 91 0.302 0.264 91 0.010
−0.264 86 0.014 −0.039 86 0.719 −0.222 86 0.038
−0.036 86 0.74 −0.167 86 0.123 0.043 86 0.697
0.316 27 0.109 −0.079 27 0.697 0.324 27 0.093
0.037 505 0.403 −0.080 499 0.074 0.060 499 0.177
−0.019 496 0.678 0.057 490 0.211 −0.037 490 0.414
−0.124 33 0.491 0.101 33 0.578 −0.154 33 0.395
0.003 31 0.986 −0.017 31 0.930 0.010 31 0.957
0.152 33 0.399 −0.103 33 0.571 0.179 33 0.318
Disease Assessment Scale Cognitive Subscale, 11-item version; AUC, Area
, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State
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the fact that p-tau decreases have been found in longitu-
dinal studies of AD [18] could also mean that this find-
ing was associated with increased neurodegeneration
due to accelerated disease. The worsening of cognition
in the face of these findings suggests that a substrate of
γ-secretase other than APP may have been responsible
for the cognitive effects. However, p-tau increased in the
placebo group more than it decreased in the treated
group, which may point to some instability in the assay.
In contrast, the correlational studies link the drug-
related change in plasma Aβ to increased brain atrophy.
Whereas such atrophy has been associated with antia-
myloid immunotherapy and could be related to reduc-
tion in inflammation or other effects of amyloid
removal, the present data link atrophy to an adverse ef-
fect on cognition consistent with a deleterious pharma-
cological effect on the disease process. Further, it must
be emphasized that these analyses do not establish caus-
ality and are confounded by dependence among the vari-
ous measures.
Similar adverse effects have been reported with an-
other γ-secretase inhibitor, avagacestat [6]. Specifically,
gastrointestinal and skin rash findings, non-melanoma
skin cancer and worsening cognition at higher doses
were observed with that drug, strongly supporting a link
to γ-secretase inhibition. The development of semagace-
stat [19,20] has been discontinued. A number of research
groups continue to pursue γ-secretase modulation and
β-site APP-cleaving enzyme 1 (or BACE) inhibition as
alternative, perhaps safer, routes to reduction of amyl-
oid peptide production.
If the adverse effects are related to off-target sub-
strates, γ-secretase modulators, which do not act at the
active site of the enzyme complex and do not interfere
with cleavage of non-APP substrates, may not carry
these risks. But the correlational analyses seem more
consistent with a direct relationship among adverse clin-
ical effects, increase in atrophy, cognitive decline and
possibly p-tau reduction.
There were correlations among peripheral and central
measures of drug level and activity and adverse effects
on cognition, consistent with related mechanisms. How-
ever, causality cannot be inferred; each of these effects is
related to drug exposure, so correlations among them
are expected. Observed drug effects could be related to
inhibition of cleavage of substrates other than APP.
Semagacestat is a non-specific inhibitor of γ-secretase,
and the half-maximal effective concentration (EC50) for
inhibition of Notch cleavage has been reported to be
similar to that for APP cleavage [21]; other methods
have indicated a tenfold stronger inhibition of Notch cleav-
age [22]. Presumably, the EC50 of semagacestat for other
transmembrane proteins that are substrates for γ-secretasemay be in the same range. On the basis of the clinical trial
results alone, the question could be raised whether a lower
dose of semagacestat given twice daily might have been
better tolerated; however, toxicology studies using beagle
dogs and rats showed that the same total daily dose of
semagacestat was tolerated very poorly when divided
into twice daily dosing due to findings consistent with
Notch-mediated gastroenteropathy (data on file, Eli
Lilly & Company). It also remains possible that inhib-
ition of γ-secretase cleavage of APP is related to the
adverse effect on cognition observed in the high-dose
arm of this trial. Further studies of γ-secretase inhibi-
tors and modulators should include monitoring for ad-
verse systemic and cognitive effects.
Progression of AD is characterized by decline in cogni-
tive performance and atrophy of brain tissue. In the
semagacestat trial, high-dose treatment had an adverse
effect on cognition [10], and in the present analyses,
cognitive decline was related to expansion of ventricular
volume. The relationship between reduction in CSF p-tau
and worsening cognition among those treated with sema-
gacestat cannot be readily explained with the available
data. Treatment effects on cognitive and biomarker mea-
sures in AD may not be predicted by the patterns of longi-
tudinal change noted in observational studies. Elucidation
of the mechanisms of these discordant effects will require
data derived from additional trials of various therapeutic
interventions, as well as more longitudinal data on
biomarker changes in mild to moderate AD.
Conclusions
Analysis of the relationships among PK/pharmacody-
namic measures, biomarkers and laboratory tests in the
phase III trial of semagacestat in mild to moderate AD
provides some insight into the neurobiological and clin-
ical impact of γ-secretase inhibition. Exposure to drug
was associated with reduction in plasma Aβ peptides, as well
as a subset of laboratory changes and adverse event rates.
Measures of brain atrophy and gastrointestinal symptoms
were related to changes in plasma Aβ peptide but not drug
concentration, supporting a link to inhibition of γ-secretase
cleavage of the APP. Cognitive decline correlated with ven-
tricular expansion and reduction in p-tau. These findings
may be useful to future investigators in the design of studies
targeting secretases involved in Aβ generation.
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